Table 4. Summary of complete and partial responses.
| Patient-regimen | Primary tumor site1 | Regimen (No.) | Response | Platinum sensitivity status | CA 125 level, U/mL | ||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Type | Duration, months | Start of regimen | End of regimen | ||||
| 12 | Peritoneum | Tamoxifen (4) | CR | 117.6 | Sensitive | 64 | 27 |
| 2 | Peritoneum | Anastrozole (2) | CR | 112.2 | Sensitive | 99 | 25 |
| 3 | Peritoneum | Letrozole (3) | CR | 67.9 | Sensitive | 52 | 9 |
| 4 | Peritoneum | Letrozole (4) | CR | 52.2 | Resistant | 109 | 134 |
| 5 | Ovary | Letrozole (3) | CR | 11.9 | Sensitive | 12 | 37 |
| 62 | Peritoneum | Letrozole (2) | CR | 42.0 | Sensitive | 8 | 6.4 |
| 7 | Ovary | Letrozole (2) | PR | 22.0 | Sensitive | 13 | 18.1 |
| 83 | Peritoneum | Letrozole (4) | PR | 1.63 | Sensitive | 13 | 9.4 |
CA125, cancer antigen 125; ER, estrogen receptor; PR, progesterone receptor; CR, complete response; PR, partial response; NA, not available
1
All patients had original histology of low-grade serous carcinoma
2
No evidence of disease as of last contact
3
Patient was responding to letrozole but stopped to enroll in a clinical trial of high-dose chemotherapy with autologous stem cell transplant.